Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys

Carsten Schröder, Agnes M. Azimzadeh, Guosheng Wu, James O. Price, James B. Atkinson, Richard N. Pierson

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Introduction: Macaque species offer a valuable model for translational allo-transplantation and tolerance studies. Cardiac allograft vasculopathy in Macaca fascicularis is associated with elaboration of anti-donor antibodies. Since T-independent pathways of B cell activation have been described, and anti-B cell strategies have proven to be a fruitful tolerogenic adjunct in rodent and xenogenic models, here we investigate whether an anti-CD20 antibody (rituximab) would be useful to deplete B-cells in a pre-clinical allo-transplantation setting in macaques. Methods: Three cynomolgus macaques which had previously rejected a cardiac allograft and one with concurrent subacute vascular rejection were treated weekly with rituximab 20 mg/kg IV for 4 and 2 weeks, respectively. B-cell levels (CD19+ cells) were measured by flow cytometry in peripheral blood, spleen, lymph node and bone marrow cells at various intervals after initiation of treatment. B-cells and plasma cells were also analyzed by immunohisto-chemistry at necropsy in spleen, lymph node, tonsil and thymus tissue sections. Anti-donor antibody liters were measured by flow cytometry. Results: B-cells expressing CD19 were not detectable in the peripheral blood in any animal within 24 h after initial treatment, or over the ensuing month. At necropsy, the germinal centers in spleen and lymph node were completely depleted of CD20+ B-cells in 2 animals, leaving a hypocellular trabecular pattern around preserved plasma cell follicles. Substantial but incomplete depletion of B-cells was demonstrated in the other 2 animals, in each instance immunohistochemical findings in spleen and lymph node exhibiting higher sensitivity for residual B-cells compared to FACS. Anti-donor antibody tilers exhibited kinetics similar to untreated animals over this short follow-up. Comment: Treatment with anti-CD20 very efficiently depletes peripheral and tissue B-cells but not plasma cells in this macaque species. Biopsy of lymph node is necessary and may be sufficient to assess B-cell clearance in secondary lymphoid organs in this model.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalTransplant Immunology
Volume12
Issue number1
DOIs
StatePublished - Oct 1 2003

Fingerprint

Macaca fascicularis
Lymphoid Tissue
B-Lymphocytes
Macaca
Lymph Nodes
Anti-Idiotypic Antibodies
Spleen
Plasma Cells
Therapeutics
Allografts
Flow Cytometry
Transplantation Tolerance
Germinal Center
Palatine Tonsil
Bone Marrow Cells
Thymus Gland
Blood Vessels
Rodentia
Transplantation
Biopsy

Keywords

  • Allo-antibodies
  • Anti-CD20 therapy
  • B-cell depletion
  • Non-human primate
  • Plasma cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Transplantation

Cite this

Schröder, C., Azimzadeh, A. M., Wu, G., Price, J. O., Atkinson, J. B., & Pierson, R. N. (2003). Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transplant Immunology, 12(1), 19-28. https://doi.org/10.1016/S0966-3274(03)00059-5

Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. / Schröder, Carsten; Azimzadeh, Agnes M.; Wu, Guosheng; Price, James O.; Atkinson, James B.; Pierson, Richard N.

In: Transplant Immunology, Vol. 12, No. 1, 01.10.2003, p. 19-28.

Research output: Contribution to journalArticle

Schröder, C, Azimzadeh, AM, Wu, G, Price, JO, Atkinson, JB & Pierson, RN 2003, 'Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys', Transplant Immunology, vol. 12, no. 1, pp. 19-28. https://doi.org/10.1016/S0966-3274(03)00059-5
Schröder, Carsten ; Azimzadeh, Agnes M. ; Wu, Guosheng ; Price, James O. ; Atkinson, James B. ; Pierson, Richard N. / Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. In: Transplant Immunology. 2003 ; Vol. 12, No. 1. pp. 19-28.
@article{9fda5e688e464d7bb978d74a61c69078,
title = "Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys",
abstract = "Introduction: Macaque species offer a valuable model for translational allo-transplantation and tolerance studies. Cardiac allograft vasculopathy in Macaca fascicularis is associated with elaboration of anti-donor antibodies. Since T-independent pathways of B cell activation have been described, and anti-B cell strategies have proven to be a fruitful tolerogenic adjunct in rodent and xenogenic models, here we investigate whether an anti-CD20 antibody (rituximab) would be useful to deplete B-cells in a pre-clinical allo-transplantation setting in macaques. Methods: Three cynomolgus macaques which had previously rejected a cardiac allograft and one with concurrent subacute vascular rejection were treated weekly with rituximab 20 mg/kg IV for 4 and 2 weeks, respectively. B-cell levels (CD19+ cells) were measured by flow cytometry in peripheral blood, spleen, lymph node and bone marrow cells at various intervals after initiation of treatment. B-cells and plasma cells were also analyzed by immunohisto-chemistry at necropsy in spleen, lymph node, tonsil and thymus tissue sections. Anti-donor antibody liters were measured by flow cytometry. Results: B-cells expressing CD19 were not detectable in the peripheral blood in any animal within 24 h after initial treatment, or over the ensuing month. At necropsy, the germinal centers in spleen and lymph node were completely depleted of CD20+ B-cells in 2 animals, leaving a hypocellular trabecular pattern around preserved plasma cell follicles. Substantial but incomplete depletion of B-cells was demonstrated in the other 2 animals, in each instance immunohistochemical findings in spleen and lymph node exhibiting higher sensitivity for residual B-cells compared to FACS. Anti-donor antibody tilers exhibited kinetics similar to untreated animals over this short follow-up. Comment: Treatment with anti-CD20 very efficiently depletes peripheral and tissue B-cells but not plasma cells in this macaque species. Biopsy of lymph node is necessary and may be sufficient to assess B-cell clearance in secondary lymphoid organs in this model.",
keywords = "Allo-antibodies, Anti-CD20 therapy, B-cell depletion, Non-human primate, Plasma cell",
author = "Carsten Schr{\"o}der and Azimzadeh, {Agnes M.} and Guosheng Wu and Price, {James O.} and Atkinson, {James B.} and Pierson, {Richard N.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0966-3274(03)00059-5",
language = "English (US)",
volume = "12",
pages = "19--28",
journal = "Transplant Immunology",
issn = "0966-3274",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys

AU - Schröder, Carsten

AU - Azimzadeh, Agnes M.

AU - Wu, Guosheng

AU - Price, James O.

AU - Atkinson, James B.

AU - Pierson, Richard N.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Introduction: Macaque species offer a valuable model for translational allo-transplantation and tolerance studies. Cardiac allograft vasculopathy in Macaca fascicularis is associated with elaboration of anti-donor antibodies. Since T-independent pathways of B cell activation have been described, and anti-B cell strategies have proven to be a fruitful tolerogenic adjunct in rodent and xenogenic models, here we investigate whether an anti-CD20 antibody (rituximab) would be useful to deplete B-cells in a pre-clinical allo-transplantation setting in macaques. Methods: Three cynomolgus macaques which had previously rejected a cardiac allograft and one with concurrent subacute vascular rejection were treated weekly with rituximab 20 mg/kg IV for 4 and 2 weeks, respectively. B-cell levels (CD19+ cells) were measured by flow cytometry in peripheral blood, spleen, lymph node and bone marrow cells at various intervals after initiation of treatment. B-cells and plasma cells were also analyzed by immunohisto-chemistry at necropsy in spleen, lymph node, tonsil and thymus tissue sections. Anti-donor antibody liters were measured by flow cytometry. Results: B-cells expressing CD19 were not detectable in the peripheral blood in any animal within 24 h after initial treatment, or over the ensuing month. At necropsy, the germinal centers in spleen and lymph node were completely depleted of CD20+ B-cells in 2 animals, leaving a hypocellular trabecular pattern around preserved plasma cell follicles. Substantial but incomplete depletion of B-cells was demonstrated in the other 2 animals, in each instance immunohistochemical findings in spleen and lymph node exhibiting higher sensitivity for residual B-cells compared to FACS. Anti-donor antibody tilers exhibited kinetics similar to untreated animals over this short follow-up. Comment: Treatment with anti-CD20 very efficiently depletes peripheral and tissue B-cells but not plasma cells in this macaque species. Biopsy of lymph node is necessary and may be sufficient to assess B-cell clearance in secondary lymphoid organs in this model.

AB - Introduction: Macaque species offer a valuable model for translational allo-transplantation and tolerance studies. Cardiac allograft vasculopathy in Macaca fascicularis is associated with elaboration of anti-donor antibodies. Since T-independent pathways of B cell activation have been described, and anti-B cell strategies have proven to be a fruitful tolerogenic adjunct in rodent and xenogenic models, here we investigate whether an anti-CD20 antibody (rituximab) would be useful to deplete B-cells in a pre-clinical allo-transplantation setting in macaques. Methods: Three cynomolgus macaques which had previously rejected a cardiac allograft and one with concurrent subacute vascular rejection were treated weekly with rituximab 20 mg/kg IV for 4 and 2 weeks, respectively. B-cell levels (CD19+ cells) were measured by flow cytometry in peripheral blood, spleen, lymph node and bone marrow cells at various intervals after initiation of treatment. B-cells and plasma cells were also analyzed by immunohisto-chemistry at necropsy in spleen, lymph node, tonsil and thymus tissue sections. Anti-donor antibody liters were measured by flow cytometry. Results: B-cells expressing CD19 were not detectable in the peripheral blood in any animal within 24 h after initial treatment, or over the ensuing month. At necropsy, the germinal centers in spleen and lymph node were completely depleted of CD20+ B-cells in 2 animals, leaving a hypocellular trabecular pattern around preserved plasma cell follicles. Substantial but incomplete depletion of B-cells was demonstrated in the other 2 animals, in each instance immunohistochemical findings in spleen and lymph node exhibiting higher sensitivity for residual B-cells compared to FACS. Anti-donor antibody tilers exhibited kinetics similar to untreated animals over this short follow-up. Comment: Treatment with anti-CD20 very efficiently depletes peripheral and tissue B-cells but not plasma cells in this macaque species. Biopsy of lymph node is necessary and may be sufficient to assess B-cell clearance in secondary lymphoid organs in this model.

KW - Allo-antibodies

KW - Anti-CD20 therapy

KW - B-cell depletion

KW - Non-human primate

KW - Plasma cell

UR - http://www.scopus.com/inward/record.url?scp=10744229262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744229262&partnerID=8YFLogxK

U2 - 10.1016/S0966-3274(03)00059-5

DO - 10.1016/S0966-3274(03)00059-5

M3 - Article

C2 - 14551029

AN - SCOPUS:10744229262

VL - 12

SP - 19

EP - 28

JO - Transplant Immunology

JF - Transplant Immunology

SN - 0966-3274

IS - 1

ER -